BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 27121025)

  • 1. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
    Barrios V; Escobar C
    Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
    Kubli KA; Snead JA; Cheng-Lai A
    Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C; Tellor KB; Armbruster AL
    Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
    Cervantes CE; Merino JL; Barrios V
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
    Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
    Weiss TW; Rohla M; Dieplinger B; Domanovits H; Fries D; Vosko MR; Gary T; Ay C
    Wien Med Wochenschr; 2018 Apr; 168(5-6):133-143. PubMed ID: 28236004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
    Dzeshka MS; Lip GY
    Expert Opin Pharmacother; 2015; 16(17):2661-78. PubMed ID: 26559069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
    Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
    Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edoxaban tosylate.
    Am J Cardiovasc Drugs; 2011; 11(2):129-35. PubMed ID: 21446778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
    Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
    De Caterina R; Agnelli G; Laeis P; Unverdorben M; Rauer H; Wang CC; Nakamura M; Chiu KM; Reimitz PE; Koretsune Y; Chen C; Thee U; Kaburagi J; Kim YH; Choi WI; Yamashita T; Cohen A; Kirchhof P
    Clin Cardiol; 2019 Dec; 42(12):1147-1154. PubMed ID: 31650560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
    Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Minguet J; Sims HM; Smith KH; Bramlage P
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.